Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1924 1
1938 1
1939 5
1940 1
1941 1
1942 1
1946 2
1947 3
1948 5
1949 2
1950 12
1951 13
1952 35
1953 21
1954 9
1955 12
1956 9
1957 22
1958 17
1959 21
1960 11
1961 13
1962 28
1963 48
1964 34
1965 42
1966 43
1967 40
1968 32
1969 40
1970 41
1971 40
1972 55
1973 60
1974 64
1975 62
1976 94
1977 84
1978 89
1979 125
1980 140
1981 169
1982 223
1983 209
1984 259
1985 294
1986 311
1987 384
1988 394
1989 428
1990 523
1991 574
1992 633
1993 752
1994 827
1995 980
1996 1115
1997 1330
1998 1483
1999 1834
2000 2162
2001 2500
2002 2988
2003 3491
2004 4169
2005 5046
2006 5802
2007 6345
2008 7426
2009 8176
2010 9255
2011 10532
2012 12081
2013 13237
2014 14838
2015 15974
2016 16988
2017 18140
2018 20192
2019 22973
2020 26623
2021 30187
2022 34428
2023 33752
2024 12847

Text availability

Article attribute

Article type

Publication date

Search Results

317,089 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Jau-Yau
Page 1
Lutetium-177-PSMA-617: A Vision of the Future.
Chandran E, Figg WD, Madan R. Chandran E, et al. Cancer Biol Ther. 2022 Dec 31;23(1):186-190. doi: 10.1080/15384047.2022.2037985. Cancer Biol Ther. 2022. PMID: 35220877 Free PMC article.
The recent VISION trial is the first to demonstrate a survival benefit of Lutetium-177[(177)Lu]Lu-PSMA-617 in post-chemotherapy mCRPC. This journal club reviews the VISION trial in the context of the earlier TheraP trial of [(177)Lu]Lu-PSMA-617 in mCRP …
The recent VISION trial is the first to demonstrate a survival benefit of Lutetium-177[(177)Lu]Lu-PSMA-617 in post-chemotherap …
[(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer.
Hennrich U, Eder M. Hennrich U, et al. Pharmaceuticals (Basel). 2022 Oct 20;15(10):1292. doi: 10.3390/ph15101292. Pharmaceuticals (Basel). 2022. PMID: 36297404 Free PMC article. Review.
In March 2022, [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)) was approved by the FDA for the treatment of prostate cancer patients. ...In numerous clinical trials, the efficacy of [(177)Lu]Lu-PSMA-617 was demonstrated....
In March 2022, [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)) was approved by the FDA for the treatment of prostate cancer patients. ...I …
Preclinical Evaluation of (68)Ga- and (177)Lu-Labeled Integrin alpha(v)beta(6)-Targeting Radiotheranostic Peptides.
Ganguly T, Bauer N, Davis RA, Foster CC, Harris RE, Hausner SH, Roncali E, Tang SY, Sutcliffe JL. Ganguly T, et al. J Nucl Med. 2023 Apr;64(4):639-644. doi: 10.2967/jnumed.122.264749. Epub 2022 Oct 7. J Nucl Med. 2023. PMID: 36207137 Free article.
Biodistribution was performed for (68)Ga-1 (1 and 2 h after injection), (68)Ga-2 (2 and 4 h after injection), and (177)Lu-1 and (177)Lu-2 (1, 24, 48, and 72 h after injection). The (177)Lu-2 biodistribution data were extrapolated for human dosimetry data esti …
Biodistribution was performed for (68)Ga-1 (1 and 2 h after injection), (68)Ga-2 (2 and 4 h after injection), and (177)Lu-1 and (177) …
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
Ruigrok EAM, van Vliet N, Dalm SU, de Blois E, van Gent DC, Haeck J, de Ridder C, Stuurman D, Konijnenberg MW, van Weerden WM, de Jong M, Nonnekens J. Ruigrok EAM, et al. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1339-1350. doi: 10.1007/s00259-020-05057-6. Epub 2020 Oct 23. Eur J Nucl Med Mol Imaging. 2021. PMID: 33094433 Free PMC article.
Autoradiography assays on cryosections of human salivary and renal tissues revealed [(177)Lu]Lu-PSMA-617 to have the lowest binding to these healthy organs compared with [(177)Lu]Lu-PSMA-I&T. ...CONCLUSION: [(177)Lu]Lu-PSMA-617 has th …
Autoradiography assays on cryosections of human salivary and renal tissues revealed [(177)Lu]Lu-PSMA-617 to have the lowest bi …
Prostate-Specific Membrane Antigen Radioligand Therapy Using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry.
Schuchardt C, Zhang J, Kulkarni HR, Chen X, Müller D, Baum RP. Schuchardt C, et al. J Nucl Med. 2022 Aug;63(8):1199-1207. doi: 10.2967/jnumed.121.262713. Epub 2021 Dec 9. J Nucl Med. 2022. PMID: 34887335 Free PMC article.
Despite the longer half-life of (177)Lu-PSMA-617, the renal dose was lower for (177)Lu-PSMA-617 than for (177)Lu-PSMA I&T (0.77 vs. 0.92 Gy/GBq, P = 0.0015). ...No nephrotoxicity was observed after either (177)Lu-PSMA I&T or (177)Lu-PSMA …
Despite the longer half-life of (177)Lu-PSMA-617, the renal dose was lower for (177)Lu-PSMA-617 than for (177)Lu-PSMA I …
Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides.
Millul J, Koepke L, Haridas GR, Sparrer KMJ, Mansi R, Fani M. Millul J, et al. Eur J Nucl Med Mol Imaging. 2023 Aug;50(10):3050-3061. doi: 10.1007/s00259-023-06272-7. Epub 2023 Jun 1. Eur J Nucl Med Mol Imaging. 2023. PMID: 37261473 Free PMC article.
Striking differences were observed in vivo regarding tumor uptake, residence, specificity, and total body distribution. All [(177)Lu]Lu-FAPI-46-based radioligands showed similar uptake between the two tumor models. [(177)Lu]Lu-FAP-2286 showed higher up …
Striking differences were observed in vivo regarding tumor uptake, residence, specificity, and total body distribution. All [(177)Lu] …
Lutetium Lu 177 Dotatate.
[No authors listed] [No authors listed] 2020 Aug 17. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2020 Aug 17. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000023 Free Books & Documents. Review.
Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. No information is available on the use of lutetium Lu 177 dotatate during breastfeeding. The ma …
Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroen …
[(177)Lu]Lu-PSMA-617 theranostic probe for hepatocellular carcinoma imaging and therapy.
Lu Q, Long Y, Gai Y, Liu Q, Jiang D, Lan X. Lu Q, et al. Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2342-2352. doi: 10.1007/s00259-023-06155-x. Epub 2023 Mar 6. Eur J Nucl Med Mol Imaging. 2023. PMID: 36877233
In the radioligand therapy study, mice were randomized into 4 groups: 37 MBq [(177)Lu]Lu-PSMA-617, 18.5 MBq [(177)Lu]Lu-PSMA-617, 7.4 MBq [(177)Lu]Lu-EB-PSMA-617, and saline (control). ...SPECT/CT and biodistribution showed that tumor upt …
In the radioligand therapy study, mice were randomized into 4 groups: 37 MBq [(177)Lu]Lu-PSMA-617, 18.5 MBq [(177)Lu] …
Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC.
Hänscheid H, Hartrampf PE, Schirbel A, Buck AK, Lapa C. Hänscheid H, et al. Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2566-2572. doi: 10.1007/s00259-020-05177-z. Epub 2021 Jan 15. Eur J Nucl Med Mol Imaging. 2021. PMID: 33452632 Free PMC article.
It was tested in selected patients whether the substance is superior to [(177)Lu]Lu-DOTA-TOC. METHODS: Activity kinetics in organs and tumours after [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC were compared intraindividually in five …
It was tested in selected patients whether the substance is superior to [(177)Lu]Lu-DOTA-TOC. METHODS: Activity kinetics in or …
Lu-177-Labeled Hetero-Bivalent Agents Targeting PSMA and Bone Metastases for Radionuclide Therapy.
Zha Z, Ploessl K, Choi SR, Zhao R, Jin W, Wang R, Alexoff D, Zhu L, Kung HF. Zha Z, et al. J Med Chem. 2023 Sep 14;66(17):12602-12613. doi: 10.1021/acs.jmedchem.3c01294. Epub 2023 Sep 5. J Med Chem. 2023. PMID: 37670407
To develop hetero-bivalent agents targeting both PSMA and bone metastasis, [(177)Lu]Lu-P17-079 ([(177)Lu]Lu-1) and [(177)Lu]Lu-P17-081 ([(177)Lu]Lu-2) were prepared. In vivo biodistribution studies of [(177)Lu]Lu
To develop hetero-bivalent agents targeting both PSMA and bone metastasis, [(177)Lu]Lu-P17-079 ([(177)Lu]Lu-1) a …
317,089 results
You have reached the last available page of results. Please see the User Guide for more information.